Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy. Results of a secondary analysis of a large scale adjuvant trial

2002 ◽  
Vol 127 (8) ◽  
pp. 661-662
2018 ◽  
Vol 10 (2) ◽  
Author(s):  
Luigina Graziosi ◽  
Marino Elisabetta ◽  
Alberto Rebonato ◽  
Annibale Donini

2016 ◽  
Vol 27 (6) ◽  
pp. 1143-1148 ◽  
Author(s):  
M. Kanai ◽  
T. Kawaguchi ◽  
M. Kotaka ◽  
K. Shinozaki ◽  
T. Touyama ◽  
...  

2002 ◽  
Vol 235 (4) ◽  
pp. 458-463 ◽  
Author(s):  
Mario Prandi ◽  
Rita Lionetto ◽  
Antonio Bini ◽  
Gianfranco Francioni ◽  
Giuseppe Accarpio ◽  
...  

2012 ◽  
Vol 50 (05) ◽  
Author(s):  
A Schöller ◽  
A Kalmár ◽  
VÁ Patai ◽  
Z Nagy ◽  
B Barták ◽  
...  

1966 ◽  
Vol 05 (02) ◽  
pp. 67-74 ◽  
Author(s):  
W. I. Lourie ◽  
W. Haenszeland

Quality control of data collected in the United States by the Cancer End Results Program utilizing punchcards prepared by participating registries in accordance with a Uniform Punchcard Code is discussed. Existing arrangements decentralize responsibility for editing and related data processing to the local registries with centralization of tabulating and statistical services in the End Results Section, National Cancer Institute. The most recent deck of punchcards represented over 600,000 cancer patients; approximately 50,000 newly diagnosed cases are added annually.Mechanical editing and inspection of punchcards and field audits are the principal tools for quality control. Mechanical editing of the punchcards includes testing for blank entries and detection of in-admissable or inconsistent codes. Highly improbable codes are subjected to special scrutiny. Field audits include the drawing of a 1-10 percent random sample of punchcards submitted by a registry; the charts are .then reabstracted and recoded by a NCI staff member and differences between the punchcard and the results of independent review are noted.


2006 ◽  
Vol 44 (05) ◽  
Author(s):  
M Rohánszky ◽  
A Nagy ◽  
G Bodoky ◽  
S Gallinger ◽  
R Gryfe

2020 ◽  
Author(s):  
Emre Yekedüz ◽  
Elif Berna Köksoy ◽  
Hakan Akbulut ◽  
Yüksel Ürün ◽  
Güngör Utkan

Aim: Using circulating tumor DNA (ctDNA) instead of historical clinicopathological factors to select patients for adjuvant chemotherapy (ACT) may reduce inappropriate therapy. Material & methods: MEDLINE was searched on March 31, 2020. Studies, including data related to the prognostic value of ctDNA in the colon cancer patients after surgery and after ACT, were included. The generic inverse-variance method with a random-effects model was used for meta-analysis. Results: Four studies were included for this meta-analysis. ctDNA-positive colon cancer patients after surgery and ACT had a significantly increased risk of recurrence compared with ctDNA-negative patients. Conclusions: ctDNA is an independent prognostic factor, and this meta-analysis is a significant step for using ctDNA instead of historical prognostic factors in the adjuvant setting.


Sign in / Sign up

Export Citation Format

Share Document